š”š²šš š¦ššŗšŗš®šæš
ā¢ Prabhudas Lilladher has recommended an accumulate rating on Zydus Lifesciences with a target price of Rs 670.
ā¢ ZYDUSLIF's Q2 EBITDA was largely in line with estimates, aided by healthy margins despite negligible gRevlimid sales.
ā¢ The company's steady domestic franchise, strong balance sheet, and potential new launches in the US are expected to help negate pricing pressure and competition in key products.